Under current guidelines, a large proportion of older people with type 2 diabetes would be recommended sodium-glucose cotransporters 2 inhibitors (SGLT2i) due to their cardiorenal benefits, and irrespective of their glycaemic control [1, 4]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.